AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Lexeo Therapeutics, Inc. Common Stock
Video analysis: LXEO
All videosNo video analysis for this stock yet. Request one from our team.
News: LXEO
BlackRock Inc. Takes Position in Lexeo Therapeutics, Inc. $LXEO
BlackRock Inc. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 5,739,455 shares of the company's stock, valued at approximately $26,717,000. BlackRock Inc. owned about 7.31% of Lexeo Therapeutics at the end of
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.
1,489,189 Shares in Lexeo Therapeutics, Inc. $LXEO Acquired by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,489,189 shares of the company's stock, valued at approximately $6,932,175,000. Lexeo Therapeutics makes up 0.1% of Avoro Capital Advisors LLC's
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalents and investments of $234.2 million expected to provide operational runway into 2028 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the second quarter 2026. “We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R.
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline
Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies
